$ less research.md

SYNOPSIS: the research record

The published record on sermorelin divides cleanly into two literatures. The first is pediatric: FDA-approval-supporting trials in children with idiopathic GH deficiency showed consistent, sustained increases in height velocity with once-daily subcutaneous dosing ^[3]. The second is aging-population pharmacodynamics: short trials in older adults showed GH and IGF-1 returning toward younger-adult values, with modest body-composition changes ^[6][7].

A third thread is mechanistic: because sermorelin acts via the pituitary receptor (GHRH-R) rather than supplying exogenous GH, physiological feedback is preserved — the pituitary remains the source, and somatostatin still caps the ceiling ^[3][10]. This property underpins both the diagnostic use (intact-pituitary reserve test) and the editorial argument for sermorelin as a physiologic secretagogue approach ^[21].

WADA-detection methods are validated. The sections below lay out each thread with citations.

MECHANISM

Sermorelin is a true GH secretagogue. It binds GHRHR — a class-B G-protein-coupled receptor expressed on anterior pituitary somatotrophs — and triggers a Gs / adenylyl cyclase / cAMP / PKA cascade. The cascade does two things: it stimulates GH gene transcription, and it releases pre-formed GH from secretory vesicles ^[3][10].

The GH pulse this produces drives hepatic IGF-1 synthesis through the GH receptor's JAK2-STAT5 axis ^[3]. IGF-1 is the principal blood biomarker of GH-axis activation and the primary downstream mediator of GH's anabolic effects ^[7].

Because the pituitary remains the source of GH, two physiological constraints stay intact. Somatostatin negative feedback continues to throttle output. Rising IGF-1 continues to provide long-loop feedback. Sermorelin cannot push GH past these ceilings the way exogenous recombinant GH can ^[3][10][12].

The peptide's short plasma half-life — approximately 11-12 minutes ^[10] — is a deliberate design property of the (1-29) fragment, not a limitation. A short-acting GHRH agonist produces a discrete pulse rather than tonic stimulation. The downstream GH pulse persists for 2-4 hours after a single subcutaneous dose, despite essentially complete clearance of the peptide itself by 60 minutes ^[10].

PHARMACOKINETICS

After a 2 mg subcutaneous dose, peak plasma sermorelin concentration is reached at 5-20 minutes ^[10]. Less than 5% of the dose remains detectable in plasma at 60 minutes ^[10]. Adult clearance is 2.4-2.8 L/min ^[10]. The plasma half-life is approximately 11-12 minutes after both subcutaneous and intravenous administration ^[10].

Class comparison: sermorelin t1/2 ~12 min, tesamorelin t1/2 ~26 min after SC dosing, CJC-1295 with DAC several days because of albumin bioconjugation ^[19]. Sermorelin's short half-life is what produces a discrete physiological GH pulse, in contrast to the more sustained elevation profiles of the longer-acting analogs ^[19].

Stability: lyophilized sermorelin acetate is stable when refrigerated (2-8°C) and protected from light. Reconstituted aqueous solution should be refrigerated and used promptly. The C-terminal amide and unprotected backbone make the peptide sensitive to proteolytic and oxidative degradation. The (1-29) fragment is more chemically stable than full-length GHRH (1-44) but is far shorter-acting than the modified GRF(1-29) backbone used in longer-acting analogs.

PEDIATRIC GROWTH-HORMONE-DEFICIENCY RECORD

The FDA-approval-supporting clinical dataset was pediatric. Once-daily subcutaneous sermorelin at 30 μg/kg given at bedtime produced sustained increases in height velocity in prepubertal children with idiopathic growth hormone deficiency ^[3]. The velocity gain was maintained through 12 months of treatment and reported through 36 months in extension cohorts. Slow-growing, shorter children with delayed bone age responded best ^[3].

A parallel pediatric study in children with idiopathic short stature — not classified as GH-insufficient — used 20 μg/kg subcutaneously twice daily for 12 months. Height velocity rose throughout treatment and returned to pretreatment values after cessation, confirming GHRH-axis dependence of the response ^[5].

Earlier mechanistic work in GH-deficient children compared continuous subcutaneous GHRH(1-29)NH2 infusion against intermittent injection over 6 months. Both promoted linear growth; the comparison demonstrated that pulsatile or repeated stimulation patterns are required for optimal somatotropic activation ^[8].

The pediatric record has been largely supplanted in clinical practice by recombinant human growth hormone, which produces larger and more predictable height-velocity gains in head-to-head comparisons. Sermorelin's responder rate and effect size were consistently smaller than rhGH's — a key reason the original sponsor exited the market in 2008 ^[2].

AGING-POPULATION STUDIES

A smaller but distinct adult literature looked at GHRH(1-29) in older adults. Khorram et al. (1997) gave a sermorelin-equivalent analog at 10 μg/kg subcutaneously nightly for 16 weeks to healthy adults aged 55-71. The trial reported significant increases in skin thickness in both sexes, a +1.26 kg increase in lean body mass in men, improved insulin sensitivity, and self-reported gains in general well-being and libido in men ^[6].

Vittone et al. (1997) gave 2 mg nightly subcutaneously for 6 weeks to healthy elderly men aged 64-76. IGF-1 elevation was evident by 2 weeks and sustained through 12 weeks, with measurable IGF-1 still present at 16 weeks post-cessation before returning to baseline. Lean body mass increased significantly in the longer-treated subgroup. The regimen was well tolerated ^[7].

Neuroendocrine work in healthy adults established that GHRH activity correlates with increased duration and intensity of slow-wave (NREM stage 3-4) sleep — the mechanistic basis for clinical observations that sermorelin-treated patients commonly report subjective sleep-quality improvements ^[15].

A 2012 trial in adults with mild cognitive impairment and healthy older adults tested tesamorelin (a GHRH(1-44) analog of the same receptor class as sermorelin) at 1 mg SC daily for 20 weeks. The trial reported a significant favorable effect on executive function vs placebo — a class-level signal for cognitive plausibility in GHRH agonists. Sermorelin itself has not been tested in a comparable powered cognitive RCT ^[14].

GHRH + GHRP SYNERGY

Co-administration of a GHRH analog with a GHS-R1a (ghrelin-receptor) agonist produces a synergistic — not merely additive — GH secretory response, several-fold greater than either agent alone ^[9]. The original demonstration paired intravenous GHRH at 1 μg/kg with intravenous GHRP-6 at 1 μg/kg in healthy human volunteers. GH peaks under combined stimulation were several-fold larger than either alone ^[9].

The pharmacodynamic basis is that the two receptors converge on the somatotroph through distinct second-messenger pathways. GHRHR signals through Gs / adenylyl cyclase / cAMP / PKA. GHS-R1a signals through phospholipase C / IP3 / intracellular calcium. Convergence on a single secretory cell produces a multiplicative output ^[9].

This dual-receptor pharmacology is the published rationale for the widely studied 'GHRH + GHRP' pairing in research-program and clinical-compounding protocols. The most commonly described pairings replace the first-generation GHRP-6 with the selective pentapeptide ipamorelin, which delivers the GH-releasing synergy without the cortisol or prolactin elevation seen with earlier GHRPs.

DIAGNOSTIC USES

Intravenous sermorelin at 1 μg/kg was the FDA-approved diagnostic provocative test for growth hormone deficiency in children ^[1][4]. It produces a rapid and relatively specific GH response with fewer false positives than several alternative provocative tests ^[4]. The diagnostic protocol samples GH at baseline and at 15, 30, 45, and 60 minutes post-injection. Subnormal responses to additional non-GHRH stimuli are required to confirm hypothalamic versus pituitary etiology, because hypothalamic GHRH-deficient patients may still respond to exogenous GHRH ^[4].

In adults, the combination of intravenous GHRH (sermorelin) at 1 μg/kg plus intravenous L-arginine at 0.5 g/kg over 30 min became one of the most accurate provocative tests for adult GH deficiency ^[11]. It was unaffected by age or sex when appropriate BMI-adjusted cutoffs were applied, and at least as sensitive as the insulin tolerance test — the historical gold standard ^[11]. The 2008 US withdrawal of sermorelin supply reduced availability and shifted adult-GHD diagnostic practice toward the glucagon stimulation test and, more recently, macimorelin ^[11].

SAFETY RECORD

Adverse events reported in sermorelin clinical trials are predominantly mild and local: transient facial flushing, redness or pain or swelling at the injection site, occasional headache, dizziness, and nausea ^[12]. Serious adverse events were rare across the pediatric and adult studies that supported FDA approval ^[12]. The safety record was preserved when the product was withdrawn for commercial reasons in 2008 — the 2013 Federal Register finding explicitly affirmed that withdrawal was not for safety or efficacy concerns ^[2].

Long-term (multi-year) safety of off-label sermorelin use in healthy aging adults has not been characterized in controlled trials. Theoretical concerns about sustained IGF-1 elevation — insulin resistance, edema, joint discomfort, neoplasia signaling — remain unresolved by the existing dataset.

ANALYTICAL DETECTION

Sermorelin is listed under Section S2 of the World Anti-Doping Code Prohibited List — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — prohibited at all times for any athlete subject to the WADA Code ^[13][18].

Validated nano-LC Orbitrap mass-spectrometric methods detect sermorelin and related GHRH analogs in athlete urine at sub-ng/mL concentrations ^[18]. The 2024 method paper addressed the analytical challenges of low urinary peptide concentration and freeze-thaw instability, and is now deployed routinely in doping control ^[18].